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Of the four strategies identified in the blueprint, American Patients First: The Trump 
Administration Blueprint to Low Drug Prices and Reduce Out-of-Pocket Costs, better 
negotiations have seen a modest amount of activity at both the federal and state level. This 
summary focuses on the actions occurring in the public space; however, activity is happening 
within commercial and private sectors as well.  
In August 2018, three months after the release of the blueprint, the Centers for Medicare & 
Medicaid Services (CMS) announced Medicare Advantage and Part D plans would be permitted 
to additional utilization management strategies than traditionally allowed. The new guidance 
allows Medicare Advantage plans the option to apply step therapy for Part B drugs, which 
includes those that are physician-administered.1 Step therapy is an approach that uses less 
expensive options first before ‘stepping up’ to more costly alternatives. Medicare Advantage 
plans that apply step therapy will be able to negotiate prices for Part B drugs, while ensuring 
their enrollees receive the most preferred drug therapy first before progressing to other therapies. 
In addition, Medicare Advantage plans will have the option to cross-manage across Part B and 
Part D drugs.1 That means that a Medicare Advantage plan may require a beneficiary to use a 
Part D drug before permitting access to a Part B therapy, or vice versa, ultimately increasing 
competition. 
Three weeks following the Medicare Advantage step therapy announcement, CMS detailed 
measures for Part D plans to allow indication-based formularies.2 Currently CMS requires that a 
Part D plan must cover all U.S. Food & Drug Administration (FDA)-approved indications for 
any drug on the formulary. The indication-based formulary design allows plans to limit a drug’s 
coverage to certain FDA-approved indications, while including alternative therapeutics for the 
drug’s non-covered indications. This change will begin in 2020 and beneficiaries can utilize 
online tools to see how indication-based formularies vary among plans before selecting a plan for 
that year.2,3 The new formulary design expands on the current utilization management strategies 
that include step therapy and prior authorization requirements. It is expected to be an 
improvement compared to the current approach of employing preferred agents as it will allow 
beneficiaries to have access to more drugs at lower negotiated prices. Our pharmacy team 
utilizes similar formulary management tools, which give clients leverage to negotiate with 
manufacturers. 
In comparison to the actions taken by CMS since the blueprint was released, novel proposals to 
improve negotiation ability have been discussed at the state level for some time. Historically, 
Medicaid pharmacy benefits must include all FDA-approved drugs so long as the manufacturer 
is entered into a federal rebate agreement. Individual states can apply prior authorizations and 
enter into supplemental rebates in order to create ‘preferred’ status within particular 
pharmacologic classes. 
Oklahoma and New York are examples of two states that have implemented innovative solutions 
to target rising drug prices. Both states acted by positioning their Medicaid pharmacy program to 
be able to more effectively negotiate with drug manufacturers through value-based pricing and 
spend capping strategies. These efforts reflect a shift seen across the payer landscape to provide 
access to new medications at prices that reflect their value. 
In June 2018, Oklahoma submitted a state plan amendment (SPA) to CMS. The SPA outlined 
their proposal for supplemental rebate agreements in the form of value-based purchasing 
arrangements.4 CMS approved this proposal as an important example of innovative actions by 
states can to lower costs. Still in the implementation stage, Oklahoma’s proposal allows the state 
to work directly with pharmaceutical companies for extra rebates based on predetermined health 
outcomes within specific patient populations.4,5 
New York implemented a different approach to control drug costs by placing an annual cap on 
Medicaid prescription spend.6 Under this approach, if New York’s Department of Health projects 
Medicaid spending will exceed the prespecified annual limit, the state Commissioner of Health 
can identify specific high cost drugs for review by the Drug Utilization Review Board. The 
Department of Health can negotiate supplemental rebates with manufacturers for these specific 
drugs. If the state and the manufacturer can’t agree on a rebate amount, and the state determines 
the cost of the drug exceeds the benefits, the state can place additional measures to limit the use 
of that drug.6,7 
Since New York implemented this annual cap strategy in August 2017, it has identified 30 drugs 
that have contributed to exceeding the spending cap. All but one of these drugs has resulted in 
successful negotiations with the respective drug company.6,7 New York’s cap on spending 
represents the first time a state Medicaid program, or any purchaser for that matter, could 
negotiate with high profile manufacturers for a drug without therapeutic alternatives. 
In September 2017, Massachusetts submitted a waiver to CMS requesting permission to use a 
closed formulary for its Medicaid program.7,8 In the waiver, MassHealth ensured that at least one 
drug option would be covered in each therapeutic class and stated that beneficiaries could still 
access non-formulary drugs for specific clinical needs. Despite their attempts, CMS turned down 
the waiver proposal. Shortly after Massachusetts submitted its waiver, Arizona sent a letter to 
CMS requesting a similar closed formulary model. In contrast to the Massachusetts proposal, 
Arizona stated that at least two drugs per category or class would be covered.7 The status of this 
request is pending. 
While no single action can tackle this issue alone, the cumulative actions taken by CMS and state 
Medicaid programs are a first important step in the larger agenda to provide patients with more 
medication choices while lowering overall drug spend. 
In December, lower list prices will be the focus of our latest blog on actions being taken to 
reduce drug prices. 
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